Literature DB >> 17116296

The protective efficacy of chlamydial protease-like activity factor vaccination is dependent upon CD4+ T cells.

Cathi Murphey1, Ashlesh K Murthy, Patricia A Meier, M Neal Guentzel, Guangming Zhong, Bernard P Arulanandam.   

Abstract

We have previously determined the protective efficacy of intranasal vaccination with chlamydial protease-like activity factor (CPAF) against genital chlamydial infection. Since T-helper 1 (Th1) responses are important for anti-chlamydial immunity, we examined the contribution of CD4(+) T cells in CPAF mediated immunity against intravaginal (i.vag.) Chlamydia muridarum infection in C57BL/6 mice. CPAF+IL-12 vaccination induced antigen-specific CD4(+) T cells that secreted elevated levels of IFN-gamma, and generated strong humoral responses. The protective effects of CPAF vaccination against genital chlamydial challenge were abrogated by anti-CD4 neutralizing antibody treatment. Moreover, anti-chlamydial immunity could be adoptively transferred to naïve recipients using CPAF-specific CD4(+) T cells. Therefore, CPAF mediated anti-chlamydial immunity is highly dependent upon antigen-specific CD4(+) T cells.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17116296      PMCID： PMC1885537          DOI： 10.1016/j.cellimm.2006.10.002

Source DB:  PubMed          Journal:  Cell Immunol        ISSN： 0008-8749            Impact factor:   4.868


  26 in total

Review 1.  Immunity to murine chlamydial genital infection.

Authors:  Richard P Morrison; Harlan D Caldwell
Journal:  Infect Immun       Date:  2002-06       Impact factor: 3.441

2.  Intranasal vaccination with pneumococcal surface protein A and interleukin-12 augments antibody-mediated opsonization and protective immunity against Streptococcus pneumoniae infection.

Authors:  B P Arulanandam; J M Lynch; D E Briles; S Hollingshead; D W Metzger
Journal:  Infect Immun       Date:  2001-11       Impact factor: 3.441

3.  Resolution of secondary Chlamydia trachomatis genital tract infection in immune mice with depletion of both CD4+ and CD8+ T cells.

Authors:  S G Morrison; R P Morrison
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

4.  IFN-gamma knockout mice show Th2-associated delayed-type hypersensitivity and the inflammatory cells fail to localize and control chlamydial infection.

Authors:  S Wang; Y Fan; R C Brunham; X Yang
Journal:  Eur J Immunol       Date:  1999-11       Impact factor: 5.532

5.  Immunity to murine Chlamydia trachomatis genital tract reinfection involves B cells and CD4(+) T cells but not CD8(+) T cells.

Authors:  S G Morrison; H Su; H D Caldwell; R P Morrison
Journal:  Infect Immun       Date:  2000-12       Impact factor: 3.441

6.  Fc receptor regulation of protective immunity against Chlamydia trachomatis.

Authors:  Terri Moore; Godwin A Ananaba; Jacqueline Bolier; Samera Bowers; Tesfaye Belay; Francis O Eko; Joseph U Igietseme
Journal:  Immunology       Date:  2002-02       Impact factor: 7.397

Review 7.  Cellular immunity and Chlamydia genital infection: induction, recruitment, and effector mechanisms.

Authors:  Kathleen A Kelly
Journal:  Int Rev Immunol       Date:  2003 Jan-Feb       Impact factor: 5.311

8.  Delivery of IL-12 intranasally leads to reduced IL-12-mediated toxicity.

Authors:  Victor C Huber; Bernard P Arulanandam; Paul M Arnaboldi; Monica K Elmore; Christine E Sheehan; Bhaskar V S Kallakury; Dennis W Metzger
Journal:  Int Immunopharmacol       Date:  2003-06       Impact factor: 4.932

9.  Fc receptor-mediated antibody regulation of T cell immunity against intracellular pathogens.

Authors:  Terri Moore; Charles O Ekworomadu; Francis O Eko; LuCinda MacMillan; Kiantra Ramey; Godwin A Ananaba; John W Patrickson; Periakaruppan R Nagappan; Deborah Lyn; Carolyn M Black; Joseph U Igietseme
Journal:  J Infect Dis       Date:  2003-07-29       Impact factor: 5.226

10.  Degradation of transcription factor RFX5 during the inhibition of both constitutive and interferon gamma-inducible major histocompatibility complex class I expression in chlamydia-infected cells.

Authors:  G Zhong; L Liu; T Fan; P Fan; H Ji
Journal:  J Exp Med       Date:  2000-05-01       Impact factor: 14.307
View more
  27 in total

1.  Protective immunity against mouse upper genital tract pathology correlates with high IFNγ but low IL-17 T cell and anti-secretion protein antibody responses induced by replicating chlamydial organisms in the airway.

Authors:  Chunxue Lu; Hao Zeng; Zhihong Li; Lei Lei; I-Tien Yeh; Yimou Wu; Guangming Zhong
Journal:  Vaccine       Date:  2011-11-10       Impact factor: 3.641

2.  Immunization with a combination of integral chlamydial antigens and a defined secreted protein induces robust immunity against genital chlamydial challenge.

Authors:  Weidang Li; Ashlesh K Murthy; M Neal Guentzel; James P Chambers; Thomas G Forsthuber; J Seshu; Guangming Zhong; Bernard P Arulanandam
Journal:  Infect Immun       Date:  2010-07-06       Impact factor: 3.441

Review 3.  Vaccination against Chlamydia genital infection utilizing the murine C. muridarum model.

Authors:  Christina M Farris; Richard P Morrison
Journal:  Infect Immun       Date:  2010-11-15       Impact factor: 3.441

4.  Intranasal vaccination with a secreted chlamydial protein enhances resolution of genital Chlamydia muridarum infection, protects against oviduct pathology, and is highly dependent upon endogenous gamma interferon production.

Authors:  Ashlesh K Murthy; James P Chambers; Patricia A Meier; Guangming Zhong; Bernard P Arulanandam
Journal:  Infect Immun       Date:  2006-11-21       Impact factor: 3.441

5.  A chlamydial type III-secreted effector protein (Tarp) is predominantly recognized by antibodies from humans infected with Chlamydia trachomatis and induces protective immunity against upper genital tract pathologies in mice.

Authors:  Jie Wang; Lili Chen; Fan Chen; Xiaoyun Zhang; Yingqian Zhang; Joel Baseman; Sondra Perdue; I-Tien Yeh; Rochelle Shain; Martin Holland; Robin Bailey; David Mabey; Ping Yu; Guangming Zhong
Journal:  Vaccine       Date:  2009-03-10       Impact factor: 3.641

6.  A T cell epitope-based vaccine protects against chlamydial infection in HLA-DR4 transgenic mice.

Authors:  Weidang Li; Ashlesh K Murthy; Gopala Krishna Lanka; Senthilnath L Chetty; Jieh-Juen Yu; James P Chambers; Guangming Zhong; Thomas G Forsthuber; M Neal Guentzel; Bernard P Arulanandam
Journal:  Vaccine       Date:  2013-10-01       Impact factor: 3.641

7.  Heat denatured enzymatically inactive recombinant chlamydial protease-like activity factor induces robust protective immunity against genital chlamydial challenge.

Authors:  Bharat K R Chaganty; Ashlesh K Murthy; Shankar J Evani; Weidang Li; M Neal Guentzel; James P Chambers; Guangming Zhong; Bernard P Arulanandam
Journal:  Vaccine       Date:  2010-01-05       Impact factor: 3.641

8.  Oral live vaccine strain-induced protective immunity against pulmonary Francisella tularensis challenge is mediated by CD4+ T cells and antibodies, including immunoglobulin A.

Authors:  Heather J Ray; Yu Cong; Ashlesh K Murthy; Dale M Selby; Karl E Klose; Jeffrey R Barker; M Neal Guentzel; Bernard P Arulanandam
Journal:  Clin Vaccine Immunol       Date:  2009-02-11

9.  Protection against Chlamydia promoted by a subunit vaccine (CTH1) compared with a primary intranasal infection in a mouse genital challenge model.

Authors:  Anja Weinreich Olsen; Michael Theisen; Dennis Christensen; Frank Follmann; Peter Andersen
Journal:  PLoS One       Date:  2010-05-21       Impact factor: 3.240

10.  A limited role for antibody in protective immunity induced by rCPAF and CpG vaccination against primary genital Chlamydia muridarum challenge.

Authors:  Ashlesh K Murthy; Bharat K R Chaganty; Weidang Li; M Neal Guentzel; James P Chambers; J Seshu; Guangming Zhong; Bernard P Arulanandam
Journal:  FEMS Immunol Med Microbiol       Date:  2009-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.